AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

The guidance hike followed forecast-beating third quarter results, with revenues up 21% on a constant currency basis to 13.57 ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

Total Revenue up 19% to $39,182m, driven by a 19% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines Total Revenue growth from Oncology was 22%, CVRM 21%, R&I ...

Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca and Daiichi Sankyo's new ...

The Centers for Disease Control and Prevention typically coordinates between 17 and 36 investigations of foodborne illnesses involving multiple states each week. A report is posted weekly, but ...

In the 630 Battle of al-Qadisiyah, the Arab army emerged victorious and continued its march into Persia, contributing to the spread of Islam beyond West Asia.